A Retrospective Study to Describe Real-World Treatment Patterns and Clinical Outcomes Among Patients With Myelodysplastic Syndromes

Bristol-Myers Squibb (BMS)

Status: Withdrawn

Conditions: Myelodysplastic Syndromes (MDS)

Treatments: Drug: Luspatercept; Drug: Epoetin Alfa

Study type: Observational

Funder types: Industry

Identifiers

NCT06581055

CA056-1083

Details and patient eligibility

About

This study aims to collect real-world data on treatment patterns and clinical outcomes for participants who discontinued Luspatercept or epoetin alfa treatment and discontinued the COMMANDS trial (NCT03682536) utilizing existing data from patient medical records.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participant was enrolled in and discontinued the COMMANDS trial.
• Participant was treated with either luspatercept or epoetin alfa and discontinued treatment while enrolled in the COMMANDS trial.
• Participant Patient provides informed consent (only where applicable or required by local regulations).

Exclusion criteria

• There are no exclusion criteria for this study.

Trial design

0 participants in 2 patient groups

Luspatercept

Description:

Adult participants treated with and discontinued Luspatercept treatment while enrolled in the COMMANDS trial (NCT03682536).

Treatment:

Drug: Luspatercept

Epoetin alfa

Description:

Adult participants treated with and discontinued Epoetin alfa treatment while enrolled in the COMMANDS trial (NCT03682536).

Treatment:

Drug: Epoetin Alfa